|1.||Jung, Hye Jin: 1 article (09/2015)|
|2.||Kim, Yonghyo: 1 article (09/2015)|
|3.||Shin, Ju Yong: 1 article (09/2015)|
|4.||Kwon, Ho Jeong: 1 article (09/2015)|
|5.||Sohng, Jae Kyung: 1 article (09/2015)|
|6.||Tanaka, Futoshi: 1 article (10/2002)|
|7.||Ochiai, Keiko: 1 article (10/2002)|
|8.||Mizukami, Tamio: 1 article (10/2002)|
|9.||Saitoh, Yutaka: 1 article (10/2002)|
|10.||Akiyama, Tadakazu: 1 article (10/2002)|
09/01/2015 - "These results suggest that herboxidiene functions as a potential antiangiogenic agent and may be applicable for anticancer therapy by targeting tumor angiogenesis. "
10/01/2002 - "Though GEX1A/herboxidiene exhibited antitumor activity in murine tumor-planted mouse models, both GEX1Q3 and GEX1Q5 did not."
09/01/2015 - "We also identified an association between the antiangiogenic activity of herboxidiene and the downregulation of both the phosphorylation of VEGF receptor 2 (KDR/Flk-1) and the expression of hypoxia-inducible factor-1α at the transcriptional level. "
09/01/2015 - "Antiangiogenic activity of herboxidiene via downregulation of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-1α."
|1.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)